Skip to main content
Clinical Trials/JPRN-UMIN000000975
JPRN-UMIN000000975
Completed
Phase 2

Expanded Treatment Efficacy and Safety Study of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Epirubicin/ Doxorubicin-Lipiodol Emulsion and Gelatin Particles: Korea-Japan Cooperative Study (JIVROSG-0604) - Expanded Treatment Efficacy and Safety Study of TACE for Unresectable HCC: Korea-Japan Cooperative Study (JIVROSG-0604)

Japan Interventional Radiology in Oncology Study Group (JIVROSG)0 sites100 target enrollmentJanuary 8, 2008

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
hepatocellular carcinoma
Sponsor
Japan Interventional Radiology in Oncology Study Group (JIVROSG)
Enrollment
100
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 8, 2008
End Date
January 1, 2012
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Japan Interventional Radiology in Oncology Study Group (JIVROSG)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Extrahepatic metastasis 2\) Hepatic vein invasion or biliary invasion 3\) Ruptured tumor 4\) Prior surgical reconstruction or endoscopic treatment of the biliary tract 5\) Clinically significant refractory ascites or pleural effusion 6\) Severe arterio\-portal or arterio\-venous shunts in the liver 7\) Allergy to contrast medium that precludes angiography 8\) Severe, active co\-morbidity, defined as follows: \- Uncontrolled cardiac failure, angina and/or rhythm disorders \- Myocardial infarction within the last 6 months \- Renal failure \- Active infection (viral hepatitis is allowed) \- Active gastrointestinal bleeding \- Other active malignant tumor \- Hepatic encephalopathy or severe mental disorder 9\) Pregnancy, nursing women, or women of childbearing potential, and men who are sexually active and not willing or able to use medically acceptable forms of contraception 10\) Not eligible because of safety issues judged by investigators

Outcomes

Primary Outcomes

Not specified

Similar Trials